Investor Database — 54,000+ VC, PE & angel contacts, the full list for $19.Get the list

Targeted Technology Fund II

Venture Capital Texas, United States

Overview

Targeted Technology Fund II is a venture capital firm focused on early-stage investments in companies that advance groundbreaking or disruptive technologies to significantly improve medical practices and patient outcomes. The firm also favors technologies that enhance the efficiency, cost-effectiveness, or functionality of developing and manufacturing life science products. The fund concentrates on sectors such as medical devices, life science tools, biotechnology, diagnostics, and specialty pharmaceuticals. It seeks technologies with the potential for a shorter time and lower cost to market, addressing compelling market needs that offer opportunities for enhanced returns. Targeted Technology Fund II's investment model aligns with the current healthcare and economic environment, favoring innovations that can improve clinical outcomes and patient care while reducing healthcare costs. The firm aims to support companies that are poised to make a significant impact in the healthcare sector through technological advancements.

Investment Focus

Early-stage healthcare technology companies
Innovative solutions in medical devices, biotechnology, diagnostics, or pharmaceuticals
Potential for significant market impact and improved patient outcomes

Portfolio Companies

Aerin MedicalBluegrass Vascular TechnologiesDNAtriXXenex

Reach Targeted Technology Fund II directly

Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.

Unlock full contacts →

Frequently asked questions about Targeted Technology Fund II

What sectors does Targeted Technology Fund II invest in?

Targeted Technology Fund II invests in Healthcare, Pharmaceuticals, Medical Devices, Diagnostics and Biotechnology, and is based in Texas, United States. Targeted Technology Fund II is listed as a venture capital in the ConnectSafely investor database.